Effects of insulin reduction with benfluorex on serum dehydroepiandrosterone (DHEA), DHEA sulfate, and blood pressure in hypertensive middle-aged and elderly men

Journal of Clinical Endocrinology and Metabolism

Volumn 80, Issue 2, 1995, Pages 700-706

  Nestler, John E ^a   Beer, Nusen A ^b   Jakubowicz, Daniela J ^b   Colombo, Claudio ^b   Beer, Rivka M ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Hospital de Clinicas Caracas   (Venezuela)

Author keywords

[No Author keywords available]

Indexed keywords

BENFLUOREX; PRASTERONE; PRASTERONE SULFATE;

ADULT; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERTENSION; INSULIN RESPONSE; INSULIN SENSITIVITY; INSULINEMIA; MAJOR CLINICAL STUDY; MALE; NOTE; ORAL DRUG ADMINISTRATION; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL;

AGED; AGING; ANDROGENS; ANTILIPEMIC AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; DEHYDROEPIANDROSTERONE; DEHYDROEPIANDROSTERONE SULFATE; FENFLURAMINE; HUMANS; HYDROCORTISONE; HYPERTENSION; INSULIN ANTAGONISTS; MALE; MIDDLE AGED; PLACEBOS;

EID: 0028835363     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jcem.80.2.7852539     Document Type: Article

References (52)

1. Carlström K, Brody S, Lunell NO, et al. 1988 Dehydroepiandros-terone sulfate and dehydroepiandrosterone in serum: differences related to age and sex. Maturitas. 10:297-306.
2. Orentreich N, Brind JL, Rizer RL, Vogelman JH. 1984 Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab. 59:551-555.
3. Orentreich N, Brind JL, Vogelman JH, Andres R, Baldwin H. 1992 Long-term longitudinal measurements of plasma dehydroepiandro-sterone sulfate in normal men. J Clin Endocrinol Metab. 75:1002-1004.
4. Migeon CJ, Keller AR, Lawrence B, Shepard TH. 1957 Dehy-droepiandrosterone and androsterone levels in human plasma. Effect of age and sex, day-to-day and diurnal variations. J Clin Endocrinol Metab. 17:1051-1062.
5. Parker LN. 1989 Adrenal androgens in clinical medicine. San Diego: Academic Press.
6. Onka J. 1976 Dehydroepiandrosterone. Metabolic effects. In: Charvát J, eds. Acta Universitatis Carolinae. Prague: Universita Karlova Praha; 1-171.
7. Lopez S A, Krehl WA. 1967 A possible interrelation between glucose-6-phosphate dehydrogenase and dehydroepiandrosterone in obesity. Lancet. 2:485-487.
8. Nowaczynski W, Fragachas F, Silah J, Millette B, Genest J. 1968 Further evidence of altered adrenocortical functions in hypertension: dehydroepiandrosterone secretion rate. Can J Biochem. 46: 1031-1038.
9. Nafziger AN, Herrington DM, Bush TL. 1991 Dehydroepiandrosterone and dehydroepiandrosterone sulfate: their relation to cardiovascular disease. Epidemiol Rev. 13:267-293.
10. Barrett-Connor E. 1992 Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus. Ann Intern Med. 117:807-811.
11. Haffner SM, Valdez RA, Mykkänen L, Stem MP, Katz MS. 1994 Decreased testosterone and dehydroepiandrosterone sulfate concentrations are associated with increased insulin and glucose concentrations in nondiabetic men. Metabolism. 43:599-603.
12. Nestler JE, Usiskin KS, Barlascini CO, Welty DF, Clore JN, Blackard WG. 1989 Suppression of serum dehydroepiandrosterone sulfate levels by insulin: an evaluation of possible mechanisms. J Clin Endocrinol Metab. 69:1040-1046.
13. Beer NA, Jakubowicz DJ, Beer RM, Arocha IR, Nestler JE. 1993 Effects of nitrendipine on glucose tolerance and serum insulin and dehydroepiandrosterone sulfate levels in insulin-resistant obese and hypertensive men. J Clin Endocrinol Metab. 76:178-183.
14. Beer NA, Jakubowicz DJ, Beer RM, Nestler JE. 1993 The calcium channel blocker amlodipine raises serum dehydroepiandrosterone-sulfate and androstenedione, but lowers serum cortisol, in insulin-resistant obese and hypertensive men. J Clin Endocrinol Metab. 76:1464-1469.
15. Nestler JE, Beer NA, Jakubowicz DJ, Beer RM. 1994 Effects of a reduction in circulating insulin by metformin on serum dehydroepiandrosterone sulfate in nondiabetic men. J Clin Endocrinol Metab. 78:549-554.
16. Beer NA, Jakubowicz DJ, Beer RM, Nestler JE. 1994 Disparate effects of insulin reduction with diltiazem on serum dehydroepiandrosterone sulfate levels in obese, hypertensive men and women. J Clin Endocrinol Metab. 79:1077-1081.
17. Nestler JE, McClanahan MA, Clore JN, Blackard WG. 1992 Insulin inhibits adrenal 17,20-lyase activity in man. J Clin Endocrinol Metab. 74:362-367.
18. Nestler JE, Kahwash Z. 1994 Sex-specific action of insulin to acutely increase the metabolic clearance rate of dehydroepiandrosterone in humans. J Clin Invest. 94:1484-1489.
19. Fink RI, Kolterman OG, Griffin J, Olefsky JM. 1983 Mechanisms of insulin resistance in aging. J Clin Invest. 71:1523-1535.
20. Shimokata H, Muller DC, Fleg JL, Sorkin J, Ziemba AW, Andres R. 1991 Age as independent determinant of glucose tolerance. Diabetes. 40:44-51.
21. Orchard TJ, Becker DJ, Kuller LH, Wagener DK, LaPorte RE, Drash AL. 1982 Age and sex variations in glucose tolerance and insulin responses: parallels with cardiovascular risk. J Chronic Dis. 35:123-132.
22. Bianchi R, Bongers V, Bravenboer B, Erkelens DW. 1993 Effects of benfluorex on insulin resistance and lipid metabolism in obese type II diabetic patients. Diabetes Care. 16:557-559.
23. Storlien LH, Oakes ND, Pan DA, Kusunoki M, Jenkins AB. 1993 Syndromes of insulin resistance in the rat. Inducement by diet and amelioration with benfluorex. Diabetes. 42:457-462.
24. Cavallo-Perin P, Estivi P, Boine L, et al. 1991 Benfluorex and blood glucose control in non-insulin-dependent diabetic patients. J Endocrinol Invest. 14:109-113.
25. Ferrannini E, Buzzigoli G, Bonadonna R, et al. 1987 Insulin resistance in essential hypertension. N Engl J Med. 317:350-357.
26. Zavaroni I, Bonora E, Pagliara M, et al. 1989 Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance. N Engl J Med. 320:702-706.
27. Pollare T, Lithell H, Berne C. 1990 Insulin resistance is a characteristic feature of primary hypertension independent of obesity. Metabolism. 39:167-174.
28. National Diabetes Data Group. 1979 Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 28:1039-1057.
29. Boden G, Chen X, Ruiz J, White JV, Rossetti L. 1994 Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest. 93:2438-2446.
30. Tielens AG, van den Heuvel JM, Schmitz MG, Geelen MJ. 1993 Effects of chronic benfluorex treatment on the activities of key enzymes of hepatic carbohydrate metabolism in old Sprague-Dawley rats. Biochem Pharmacol. 46:1539-1544.
31. Lacour F, Espinal J, Arnaud O, Duhault J. 1993 Improvement in glucose tolerance of insulin resistant rats after chronic or acute administration of benfluorex. Life Sci. 53:1525-1529.
32. Serradas P, Blondel O, Bailbe D, Portha B. 1993 Benfluorex normalizes hyperglycemia and reverses hepatic insulin resistance in STZ-induced diabetic rats. Diabetes. 42:564-570.
33. Bailey CJ, Page T, Day C, Thombum CC. 1992 Acute effect of benfluorex on glucose metabolism. Biochem Pharmacol. 44:379-382.
34. Nestler JE, Clore JN, Blackard WG. 1992 Dehydroepiandrosterone: the "missing link" between hyperinsulinemia and atherosclerosis? FASEB J. 6:3073-3075.
35. Barrett-Connor E, Khaw KT, Yen SSC. 1986 A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. N Engl J Med. 315:1519-1524.
36. Herrington DM, Gordon GB, Achuff SC, et al. 1990 Plasma de-hydroepiandrosterone and dehydroepiandrosterone sulfate in patients undergoing diagnostic coronary angiography. J Am Coll Cardiol. 16:862-870.
37. Mitchell LE, Sprecher DL, Borecki IB, Rice T, Laskarzewski PM, Rao DC. 1994 Evidence for an association between dehydroepiandrosterone sulfate and nonfatal, premature myocardial infarction in males. Circulation. 89:89-93.
38. Reaven GM. 1988 Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 37:1595-1607.
39. DeFronzo RA, Ferrannini E. 1991 Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerotic cardiovascular disease. Diabetes Care. 14:173-194.
40. Slowinska-Srzednicka J, Zgliczynski S, Ciswicka-Sznajderman M, et al. 1989 Decreased plasma dehydroepiandrosterone sulfate and dihydrotestosterone concentrations in young men after myocardial infarction. Atherosclerosis. 79:197-203.
41. Ishihara F, Hiramatsu K, Shigematsu S, et al. 1992 Role of adrenal androgens in the development of arteriosclerosis as judged by pulse wave velocity and calcification of the aorta. Cardiology. 80: 332-338.
42. Gordon GB, Bush DE, Weisman HF. 1988 Reduction of atherosclerosis by administration of dehydroepiandrosterone. A study in the hypercholesterolemic New Zealand White rabbit with aortic intimai injury. J Clin Invest. 82:712-720.
43. Arad Y, Badimon JO, Badimon L, Hembree W, Ginsberg HN. 1989 Dehydroepiandrosterone feeding prevents aortic fatty streak formation and cholesterol accumulation in cholesterol-fed rabbit. Arteriosclerosis. 9:159-166.
44. Eich DM, Nestler JE, Johnson DE, et al. 1993 Inhibition of accelerated coronary atherosclerosis with dehydroepiandrosterone in the heterotopic rabbit model of cardiac transplantation. Circulation. 87: 261-269.
45. Saenger P, New M. 1977 Inhibitory action of dehydroepiandrosterone (DHEA) on fibroblast growth. Experientia. 33:966-967.
46. Nestler JE, Barlascini CO, Clore JN, Blackard WG. 1988 Dehydro-epiandrosterone reduces serum low-density lipoprotein levels and body fat but does not alter insulin sensitivity in normal men. J Clin Endocrinol Metab. 66:57-61.
47. Jesse R, Nestler JE, Eich D, Hess M. 1991 Dehydroepiandrosterone in vivo and in vitro inhibits platelet aggregation [Abstract], J Am Coll Cardiol. 17(Suppl A):376A.
48. Manicardi V, Camellini L, Bellodi G, Coscelli C, Ferrannini E. 1986 Evidence for an association of high blood pressure and hyperinsulinemia in obese man. J Clin Endocrinol Metab. 62: 1302-1304.
49. Reaven GM. 1991 Insulin resistance, hyperinsulinemia, hypertriglyceridemia, and hypertension. Parallels between human disease and rodent models. Diabetes Care. 14:195-202.
50. Haffner SM. 1993 Editorial: insulin and blood pressure: fact or fantasy? J Clin Endocrinol Metab. 76:541-543.
51. Landin K, Tengbom L, Smith U. 1991 Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors. J Intern Med. 229:181-187.
52. Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. 1994 Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism. 43:647-654.